Overall, these results demonstrate the therapeutic potential of IL-2 and anti-TGF-β to meaningfully accelerate NK cell reconstitution and function without treatment-related toxicities resulting in greater protection from cancer relapse. This evidence concerns the gene IL2 and cancer.